Patent · US Active

Claudin18 antibodies and methods of treating cancer

US11834499B1 · kind B1 · utility

1Cited by

0References

99Claims

0Family size

Assignee

The Regents of the University of California · US

Inventors

Dylan Conklin · Los Angeles, US
Martina S. McDermott · Los Angeles, US
Neil A. O'Brien · Los Angeles, US
Michael J. Palazzolo · Los Angeles, US
Dennis Slamon · Los Angeles, US

Key dates

Filing date	Oct 3, 2022
Grant date	Dec 5, 2023
Priority date	—
Expiry date	Oct 3, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure provides antigen-binding proteins which bind to Claudin-18.2 (CLDN18.2); bispecific antigen-binding proteins which bind to CLDN18.2 and a second antigen; and conjugates thereof. In various aspects, the antigen-binding proteins bind to Extracellular Loop 1 (EL1) of the extracellular domain of CLDN18.2. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.